Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Analysis of Circulating Tumor Markers in the Blood

Trial Profile

Analysis of Circulating Tumor Markers in the Blood

Phase of Trial: Phase II

Latest Information Update: 08 Dec 2018

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Fulvestrant; Palbociclib
  • Indications Advanced breast cancer; Colorectal cancer; Lung cancer; Non-small cell lung cancer; Solid tumours; Uveal melanoma
  • Focus Biomarker; Pharmacodynamics; Proof of concept
  • Acronyms ALCINA
  • Most Recent Events

    • 11 May 2017 New trial record
    • 29 Apr 2017 Results of circulating tumor DNA changes (n=15) published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top